Market Cap: $22.95M
IL
Immutep Limited
IMMP
NASDAQUSD
Market Cap: $22.95M
Immutep Faces Legal Scrutiny After Phase III Study Termination Immutep Ltd. is currently under investigation by the Rosen Law Firm, a leading global entity specializing in investor rights, over allega…
Immutep Faces Critical Juncture in TACTI-004 Phase 3 Trial Immutep Limited, a biopharmaceutical company focusing on immunotherapy for cancer treatment, currently stands at a pivotal point as it naviga…
Immutep's TACTI-004 Trial Update Raises Concerns Immutep Limited's recent update regarding its TACTI-004 Phase 3 trial brings significant attention to the challenges that biotech companies face during…
Immutep Advances in Autoimmune Disease Treatment with IMP761 Trial Update Immutep Limited (NASDAQ: IMMP) announces a significant update on its Phase I clinical trial for IMP761, a groundbreaking LAG-3…
Immutep Advances Autimmune Treatment with Promising Phase I Trial of IMP761 Immutep Limited is currently making significant strides in the field of immunotherapy with its Phase I clinical trial of IMP…
Immutep's Innovative Approach in NSCLC Treatment Shows Promise Immutep Limited (IMMP) recently announces significant findings from the INSIGHT-003 trial, which explores a novel triple combination ther…